← Oncology Approval Tracker

FDA DECISION ·

Adcetris

brentuximab vedotin · Seagen (Pfizer)

FDA approvalNew or expanded indicationLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma after two or more systemic lines who cannot undergo autologous transplant or CAR T-cell therapy; eligible histologies include DLBCL not otherwise specified, DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma.

LAMPGEN ANALYSIS

Why it matters

The combination provides a CD30-directed antibody–drug conjugate regimen for heavily pretreated patients who cannot proceed to cellular therapy.

What research teams should watch

Capture the reason for transplant or CAR T ineligibility and coordinate oral lenalidomide dispensing with infusion visits.

PRIMARY RECORDS

Sources